Reports Q3 revenue $3.2M, consensus $4.92M. “As we disclosed in June 2023, we continue to seek financial resources to advance avexitide in post-bariatric hypoglycemia, or PBH, where we see the highest revenue potential, have demonstrated proof-of-concept in Phase 2 clinical trials, and have FDA alignment on Phase 3 endpoints, sample size, and study design,” said David Apelian, CEO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EIGR:
- Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
- Eiger BioPharmaceuticals, Inc. (EIGR) Q3 Earnings Cheat Sheet
- Eiger BioPharmaceuticals down 27% at 51c per share after resumption of trade
- Eiger BioPharmaceuticals trading resumes
- Eiger BioPharmaceuticals to resume trading at 4:35 pm ET
